Global Enteral Feeding Formulas Market to Grow at a CAGR of 7.33% During 2022–2030

Introduction

Enteral nutrition/feeding is most commonly referred to as tube feeding. The gastrointestinal tract is used in enteral feeding, and the formula can be given orally or through a feeding tube. Tube feeding delivers nourishment and food to the body that can replace eating solid foods or following a typical diet.

Market Dynamics

Increasing Prevalence of Metabolic and Chronic Diseases Drives the Global Market

According to the World Health Organization's (WHO) 2021 information sheet, non-communicable diseases (NCDs), or chronic diseases, cause 71% of worldwide deaths, or 41 million deaths annually. Furthermore, Americans with chronic illnesses are the most common visitors to hospitals and clinics. Inadequate nutrition and gastrointestinal issues are likely to occur in cancer patients due to several treatments and procedures. This problem can be lessened by the nutritionally supportive method of enteral feeding formulations.

Entrance of New Products and Growing Innovation Creates Tremendous Opportunities

The number and diversity of enteral formulas used have substantially risen during the past 25 years. Currently, more than 1,000 enteral formulae are accessible, and companies are releasing new goods to cater to a broader customer base. Abbott is one company that has responded to the demand for nutritional food mix formulas for tube-fed patients by launching the PediaSure Harvest product and Ensured Harvest in 2019. These products feature a novel combination of real-food ingredients from sources like mango, spinach, carrot, pumpkin, and banana. Given the growing understanding of illness physiopathology, constituent composition, and functional properties, additional innovation is also conceivable. These factors are anticipated to drive market growth during the forecast period.

Regional Analysis

North America is the most significant shareholder in the global enteral feeding formulas market and is expected to grow at a CAGR of 7.46% during the forecast period. Chronic conditions like diabetes, cardiovascular disease, and kidney problems are prevalent in the United States. This factor strongly impacts the market growth and the nation's rapidly increasing older population. It is also hoped that the involvement of significant businesses, like Victus Inc., Abbott Laboratories, Trovita Health Science, and Mead Johnson & Company LLC, will help to grow the examined market in the country. More than 432,000 Canadians 65 and older had dementia with a diagnosis, including Alzheimer's, according to a report from the Public Health Agency of Canada 2020.

Europe is expected to grow at a CAGR of 7.28%, generating USD 3,898.44 million during the forecast period. Chronic disease burden is expected to rise due to Germans' changing lifestyle patterns, which include consuming too much sugar and starches, not exercising enough, eating poorly, etc. Due to the numerous issues, such as cardiovascular illnesses, diabetes, etc., the market for enteral feeding formulas is predicted to grow. In Germany, many companies sell enteral feeding formulas. For instance, the German business Fresenius Kabi AG offers a variety of powder products, ready-to-use tube feeds, and oral nutritional supplements (ONS), including Fresubin (Standard), Fresubin DM, and Kabipro. The French government established the "French National Nutrition and Health Program (PNNS)" to improve public health and reduce disease risk. In light of the increased prevalence of diseases and government initiatives, it is anticipated that the market for enteral feeding formulae will expand over the projected year.

Asia-Pacific is expected to grow significantly during the forecast period. One of the primary factors influencing the growth of the enteral feeding formula market is the increased incidence of cancer and other chronic illnesses in China, where patients require tube feeding since they are unable or unwilling to consume food orally. The leading market participants are spending on development because so many illnesses are prevalent in this region, which presents business chances. A May 2020 article from the University of Health and Welfare in Niigata, Japan, estimates that there are 40,000 cases of Chron's disease and 140,000 cases of ulcerative colitis in Japan, with the prevalence of inflammatory bowel diseases rising. Due to the market's growing acceptance of enteral feeding formula, important manufacturers are also creating new product launches and pursuing marketing authorization.

Key Highlights

• The global enteral feeding formulas market was valued at USD 7,229.89 million in 2021. It is projected to reach USD 13,665.38 million by 2030, growing at a CAGR of 7.33% during the forecast period (2022-2030).
• Based on product, the global enteral feeding formulas market is bifurcated into standard formulas and disease-specific formulas. The standard formulas segment is the highest contributor to the market and is expected to grow at a CAGR of 7.24% during the forecast period.
• Based on application, the global enteral feeding formulas market is bifurcated into oncology, neurology, critical care, diabetes, gastroenterology, and other applications. The oncology segment owns the highest market share and is expected to grow at a CAGR of 7.61% during the forecast period.
• Based on end-user, the global enteral feeding formulas market is bifurcated into hospitals, home care agencies and hospices, and other end-users. The hospital segment is the highest contributor to the market and is expected to grow at a CAGR of 7.61% during the forecast period.
• North America is the most significant shareholder in the global enteral feeding formulas market and is expected to grow at a CAGR of 7.46% during the forecast period.

Competitive Players

Competitive Players

The global enteral feeding formulas market’s major key players are. Abbott Laboratories, B. Braun Melsungen AG, Danone SA (Nutricia), FRESENIUS SE & CO. KGAA (Fresenius Kabi AG), Global Health Product Inc., Reckitt Benckiser Group plc. (Mead Johnson), Meiji Holdings Co. Ltd, Nestle SA, Trovita Health Science, and Victus Inc.

Recent Developments

Market News

• In February 2022, Fidmi Medical Ltd., a portfolio company of The Trendlines Group ("Trendlines"), announced that it received an investment of USD 2 million from B. Braun Melsungen AG ("B. Braun"). Fidmi Medical developed a new, low-profile enteral feeding device (nutrition through a tube) that overcomes the drawbacks of existing solutions.
• In April 2022, Fresenius Kabi launched a NEW Enteral Nutrition Product App!
• In July 2022, Danone announced the launch of the first-ever Dairy and Plants Blend baby formula in response to parents’ desire for vegetarian and flexitarian options for their babies.

Segmentation

Global Enteral Feeding Formulas Market: Segmentation

By Products

• Standard Formulas
• Disease-specific Formulas

By Applications

• Oncology
• Neurology
• Critical Care
• Diabetes
• Gastroenterology
• Other Applications

By End-User

• Hospital
• Home Care Agencies and Hospices
• Other End Users

By Regions

• North America
• Europe
• Asia-Pacific
• LAMEA